Alpha 2.0
Login Register
» Authors » Jun Miki

Jun Miki

Explore the profile of Jun Miki including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 189
Citations 914
Followers 0
Related Specialties
Urology
Oncology
Nephrology
Top 10 Co-Authors
Takahiro Kimura
Takafumi Yanagisawa
Fumihiko Urabe
Shin Egawa
Kosuke Iwatani
Wataru Fukuokaya
Keiichiro Mori
Shunsuke Tsuzuki
Shoji Kimura
Hiroki Yamada
Published In
Int J Urol
Urol Oncol
Nephrology (Carlton)
Int J Clin Oncol
Clin Genitourin Cancer
Affiliations
Soon will be listed here.
Recent Articles
11.
Clinical outcomes and treatment patterns of maintenance avelumab in locally advanced or metastatic urothelial carcinoma: a multicenter collaborative study
Taneda Y, Urabe F, Uchida N, Kadena S, Shibata K, Hashimoto M, et al.
Jpn J Clin Oncol . 2025 Jan; PMID: 39820356
Background: The JAVELIN Bladder 100 trial demonstrated improved overall survival (OS) with maintenance avelumab in patients with locally advanced or metastatic urothelial carcinoma UC (la/mUC) who achieved disease control following...
12.
Comparison of oncological outcomes between extended and no pelvic lymph node dissection in patients with high- or very high-risk prostate cancer: a multi-institutional study
Washino S, Kawase M, Shimbo M, Yamasaki T, Ohba K, Miki J, et al.
Prostate Int . 2025 Jan; 12(3):160-166. PMID: 39816941
Background: Despite providing valuable staging and prognostic information, the therapeutic benefit of pelvic lymph node dissection (PLND) remains uncertain. We sought to assess the effect of extended PLND (ePLND) on...
13.
Initial experience of a novel surgical assist robot "Saroa" featuring tactile feedback and a roll-clutch system in radical prostatectomy
Iwatani K, Urabe F, Saito S, Kawano S, Yamasaki T, Kimura S, et al.
Sci Rep . 2024 Dec; 14(1):31727. PMID: 39738294
To evaluate the safety and efficacy of the Saroa Surgical Robot System in robot-assisted laparoscopic radical prostatectomy (RARP). We enrolled 60 patients who underwent RARP using either the Saroa (n...
14.
Predicting pathological upstaging after radical nephroureterectomy in patients with upper tract urothelial carcinoma: results from a multicenter cohort study
Yamaguchi R, Kagawa H, Yoshihara K, Yamamoto S, Hara S, Miyajima K, et al.
Transl Androl Urol . 2024 Dec; 13(11):2384-2395. PMID: 39698572
Background: Despite the availability of advanced imaging technologies, it remains difficult to achieve sufficient staging accuracy to ensure a tailored treatment strategy for patients with upper tract urothelial carcinoma (UTUC)....
15.
Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Matched Cohort Studies
Matsukawa A, Yanagisawa T, Miszczyk M, Kardoust Parizi M, Fazekas T, Tsuboi I, et al.
Eur Urol Focus . 2024 Nov; PMID: 39578213
Background And Objective: Radical cystectomy (RC) is the standard treatment for muscle-invasive bladder cancer (MIBC). It is highly invasive and associated with perioperative risks, while bladder-preserving trimodality therapy (TMT) offers...
16.
Central Nervous System Toxicity in Prostate Cancer Patients Treated with Androgen Receptor Signaling Inhibitors: A Systematic Review, Meta-analysis, and Network Meta-analysis
Matsukawa A, Yanagisawa T, Rajwa P, Fazekas T, Miszczyk M, Tsuboi I, et al.
Clin Genitourin Cancer . 2024 Nov; 23(1):102251. PMID: 39571519
Background: Androgen-receptor signaling inhibitors (ARSIs) significantly improve survival in systemic therapy for advanced/metastatic prostate cancer (PCa) patients; however possible central nervous system (CNS) toxicity is an unaddressed concern. We aimed...
17.
Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta-analysis, and Network Meta-analysis
Yanagisawa T, Mori K, Matsukawa A, Kawada T, Katayama S, Laukhtina E, et al.
Target Oncol . 2024 Nov; 20(1):57-69. PMID: 39535690
Context: Adjuvant immune checkpoint inhibitors (ICIs) have recently emerged as guideline-recommended treatments of high-risk muscle-invasive urothelial carcinoma (MIUC). However, there is limited evidence regarding the optimal candidates and the differential...
18.
Optimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative study
Hara S, Urabe F, Tashiro K, Goto Y, Iwamoto Y, Ohtsuka T, et al.
Jpn J Clin Oncol . 2024 Oct; 55(2):158-163. PMID: 39426804
Objective: We determined the optimal timing for initiating androgen receptor signaling inhibitor (ARSI) therapy in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and assessed its impact on oncological outcomes. Materials...
19.
Clinical significance of PSA dynamics in castration-sensitive prostate cancer treated with ARSI doublet therapy: A multicenter study
Urabe F, Hatakeyama S, Yanagisawa T, Narita S, Muramoto K, Katsumi K, et al.
Urol Oncol . 2024 Oct; 43(4):271.e9-271.e18. PMID: 39389903
Background: Androgen receptor signaling inhibitors (ARSIs) have revolutionized the treatment of metastatic castration-sensitive prostate cancer (mCSPC). Prostate-specific antigen (PSA) dynamics, including PSA nadir, PSA response rate, and time to PSA...
20.
Reproductive organ involvement in women undergoing radical cystectomy for urothelial bladder cancer: a nationwide multicenter study
Kato M, Taoka R, Miki J, Saito R, Fukuokaya W, Matsui Y, et al.
Int J Clin Oncol . 2024 Oct; 29(12):1937-1945. PMID: 39379757
Background: Radical cystectomy in women generally includes the removal of the uterus, ovaries, and anterior vaginal wall, but the criteria for reproductive organ sparing are not clear. Methods: A total...